

Isturisa® (osilodrostat) - Expanded indication

- On April 16, 2025, <u>Recordati announced</u> the FDA approval of <u>Isturisa (osilodrostat)</u>, for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.
 - Isturisa was previously approved for adult patients with Cushing's disease for whom
 pituitary surgery is not an option or has not been curative.
- The recommended initial dose of Isturisa is 2 mg orally twice daily. The maintenance dosage is individualized and determined by titration based on cortisol levels and patient's signs and symptoms.
 - The maintenance dosage varied between 2 mg and 7 mg twice daily in clinical trials.
 - The maximum recommended maintenance dosage of Isturisa is 30 mg twice daily.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.